OWP Pharmaceuticals Announces a Second IND Approval and Patent Application: The First-Ever Liquid Oral Suspension Formulation of Lamotrigine for the Treatment of Epilepsy and Bipolar Disorder
December 03, 2019 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Dec. 03, 2019 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...